High Dephosphorylated-Uncarboxylated MGP in Hemodialysis patients: risk factors and response to vitamin K2, A pre-post intervention clinical trial.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a clinical trial.

The aim of this study is to assess first the drop of dp-ucMGP in an Eastern Mediterranean cohort after vitamin K2 treatment and second the correlation between baseline dp-ucMGP and vascular calcification score.

Why It Was Studied

Vascular calcifications are highly prevalent in hemodialysis patients.

The clinical trial was registered on clinicaltrials.gov (Identification number NCT02876354, on August 11, 2016).

Who Took Part

According to the abstract, 50 patients were involved.

By PubMed's age tags, the people studied were middle-aged adults, older adults and people over 80, both men and women.

How the Study Was Run

At baseline they were assessed for plasma dp-ucMGP levels and vascular calcification scores (AC-24) as well as for other demographic, clinical and biological variables.

Dp-ucMGP levels were measured a second time at 4 weeks.

What Was Measured

Topics PubMed links to this paper include Biomarkers, Calcium-Binding Proteins, Extracellular Matrix Proteins, Phosphorylation, Renal Dialysis, Risk Factors and Vitamin K 2.

Author keywords: Dephosphorylated Uncarboxylated matrix Gla protein, Hemodialysis, Menaquinone-7, Pre-post intervention clinical trial, Vascular calcifications and Vitamin K2.

What This Means in Plain Language

This is a clinical trial of Vitamin D, K2, Magnesium and Zinc in 50 patients.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2017 (BMC nephrology), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.